ABBV-8E12/Tilavonemab [231] and Gosuranemab [232], two monoclonal Abs (mAbs) with a tau clearing function, exhibited promising Tau clearance and reversal of cognitive impairment in mouse models. This evidence concerns the gene MAPT and Cognitive impairment.